T6390

Anagrelide hydrochloride (BL4162A) serves as a treatment for essential thrombocytosis.

VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.

Axl-IN-8 (NO.1) is a potent AXL inhibitor (IC50 < 1 nM) and also inhibits c-MET (IC50: 1-10 nM).

XP-524 is a potent inhibitor of BET and EP300. XP-524 has significant tumouricidal effects in vivo, preventing KRAS-induced tumour transformation in vivo and prolonging survival in two aggressive PDAC transgenic mouse models. XP-524 also enhances the expression of its own peptide and recruitment of tumour cells to cytotoxic T lymphocytes. XP-524 has shown potential for research in pancreatic ductal adenocarcinoma (PDAC).

ATX inhibitor 19 is a potent inhibitor of ATX (IC50: 156 nM).

Hesperadin hydrochloride is an ATP-competitive indolone inhibitor of Aurora A and B, with an IC50 value of 250 nM for Aurora B.

hGGPPS-IN-2 is an analogue of C-2 substituted thienopyrimidinyl bisphosphonates (C2-ThP-BPs) and is a potent inhibitor of human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 targets multiple myeloma (MM) cells, induces selective apoptosis, and shows anti-myeloma effects in vivo. It has shown anti-myeloma effects in vivo.

PDE5/HDAC-IN-1 is a potent inhibitor of phosphodiesterase 5 (PDE5) and HDAC, with IC50 values of 46.3 nM and 14.5 nM, respectively.

hCAII-IN-4 (Compound 12j) is a potent inhibitor of human carbonic anhydrase II (hCA II) with an IC50 of 7.78 μM, and also inhibits β-glucuronidase with an IC50 of 773.9 μM [1].

GLP-1R agonist 3 is a potent imidazole derivative and GLP-1R agonist with demonstrated research potential in diabetes. [Thickened]